Medigate Raises $30M to Meet Exploding Demand

Medigate is the first and leading medtech offering dedicated medical device security and asset management platform, enabling providers to deliver secure, connected care. Medigate fuses the knowledge and understanding of medical workflow and device identity and protocols with the reality of today’s cybersecurity threats. With Medigate, hospital networks can safely operate all medical devices on their network, enabling deployment of existing and new devices to patients while ensuring privacy and safety.

Medigate’s vision has always been to revolutionize device security forthe Internet of Things (IoT) in healthcare allowing institutions to securelydeploy and manage any device on the network while maintaining continuity ofcare. Medigate's growth has been enormous and it has been receiving international acclaim with awards and recognition coming from companies such as SINET and Forbes to name a few. 

The company has announced that it has closed $30M in new financing in a Series B round led by Partech with existing investors YL Ventures, U.S. Venture Partners (USVP), Blumbering Capital and Maor investments also participating. This brings their total funding to an impressive $50M. The new funds will be used to meet the exploding demand of healthcare organizations needing advancedprotection, visibility and cost control as they tackle the present pandemic andplan for the future. This investment will expand Medigate’s position asthe leading healthcare security and clinical analytics company in the US andglobally.

“Medigate’s innovative approach to device visibility, security and management is giving hospitals confidence they can secure and manage the devices they’re connecting to their network,” said Jean Sini, general partner at Partech. “Their growth over the last two years is evidence that securing unmanaged devices is top of mind for healthcare leaders.”

Congratulations to everyone at Medigate, we are so pleased to have you in our portfolio!

Read the full press release here. 

Subscribe to our Newsletter now!